10 Turnarounds That Haven’t Turned Around: Pfizer (PFE, MRK, BMY, JNJ)

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Early this week we are running a list of stocks that have been in a turnaround plan, yet the stocks and the businesses haven’t turned around.  Could these be the stocks to watch for 2008?

Pfizer (NYSE:PFE) is perhaps the most troubled Big Pharma.  It has been in a turnaround that just hasn’t turned.  Many expect the pressure to stay into 2008 as well.  This has patents expiring sooner rather than later, competitors still taking market share in some of its historical key winning blockbuster drugs, and a lack of any serious drug pipeline.  Hey, that is Pfizer.  Its CEO is still fairly new but hasn’t ever made a dent here.  This is VERY hard to turn because its market cap is $157 Billion so the law of large numbers is a hitch.   

Pfizer sold off its consumer products unit for some $16 Billion to J&J (NYSE:JNJ) to be a pure drug company.  That hasn’t managed to help and may have in fact been the wrong play since its drug growth seems limited.  Maybe that consumer products company was one of the more steady businesses after all.  Pfizer is going to need to do not one big biotech deal, but may need two or three key deals so that it can transform and show some more promise ahead.  Analysts aren’t looking for anything in 2008, so any upside might be the difference.

Troubled drug companies can overcome adversity, even when things are mounting against them.  We wouldn’t even be surprised if the company issues more pink slips and cost cutting measures.  Merck (NYSE:MRK) was thought to be in the same boat a few years ago and it has come screaming back with a vengeance.  Even Bristol-Myers Squibb (NYSE:BMY) managed to get off of its low-$20’s base.  Yet Pfizer is just stuck in the low-$20’s to mid-$20s and it’s been a pig for over 3-years now.  If the company can find a few deals with promise for growth into 2009 and beyond, investors may start to take cash out of Merck and direct it the way of Pfizer.

Sign up for our own open email distribution list covering buyouts, spin-offs, unusual options activity, special situation previews, merger-arb spreads, and more.

Jon C. Ogg
December 17, 2007

JOn Ogg can be reached at [email protected]; he produces the SPECIAL SITUATION newsletter and he does not own securities in the companies he covers.

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618